Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
Business Wire•11/11/2026•08:46 ET
1
Key Highlights
- ➤Guardant360 Liquid adds five epigenomic applications for breast and lung cancer treatment selection
- ➤Two predictors identify potential SERD and ICI monotherapy beneficiaries without traditional biomarkers
- ➤Epigenomics identifies 20-45% of ALK fusions missed by genomic liquid testing alone
- ➤Epigenomics detects over 250% more MTAP deletions than genomic liquid testing alone
- ➤Blood-based PD-L1 assessment may identify NSCLC patients needing chemotherapy plus immunotherapy
Expert Statements
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“By bringing genomics, epigenomics and AI together, Guardant is trailblazing a new standard of oncology care”
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“Our goal is to translate deeper biological insights into practical information that gives physicians greater confidence in treatment decisions and brings us toward the fulfillment of what precision medicine can be.”
Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360(®) Liquid
* Powered by InfinityAI, expanded capabilities bring together genomics and epigenomics to inform therapy selection in breast and lung cancers and identify additional treatment opportunities
Get started
Create a free account to read the full story.